Suppr超能文献

揭示微生物群和粪便微生物群移植在克罗恩病中的作用:当前进展与未来障碍

Uncovering the role of microbiota and fecal microbiota transplantation in Crohn's disease: Current advances and future hurdles.

作者信息

Singh Jai P, Aleissa Maryam, Chitragari Gautham, Drelichman Ernesto Raul, Mittal Vijay K, Bhullar Jasneet Singh

机构信息

Department of Surgery, Henry Ford Providence Hospital, Michigan State University College of Human Medicine, Southfield, MI 48075, United States.

出版信息

World J Methodol. 2025 Dec 20;15(4):106148. doi: 10.5662/wjm.v15.i4.106148.

Abstract

Crohn's disease (CD) is an idiopathic, chronic, and recurrent inflammatory condition of the gastrointestinal tract. Recent studies suggest a potential role of gut microbiota in CD, particularly dysbiosis-an imbalance in gut bacteria. While dysbiosis is consistently observed in CD, it remains uncertain whether it is a cause or a consequence of the disease. Given its association with CD, the therapeutic potential of fecal microbiota transplantation (FMT) has been explored. This review examines the role of gut microbiota in CD, evaluates the therapeutic potential of probiotics and FMT, and highlights current research findings and limitations. Key studies on the relationship between gut dysbiosis, probiotics, and FMT in CD were analyzed, with a focus on randomized trials, meta-analyses, and clinical observations. Dysbiosis is a consistent feature of CD, but its causative role remains unclear. Probiotics, prebiotics, and synbiotics have shown no efficacy in inducing or maintaining remission in CD. FMT shows potential as a therapeutic option for CD, but its efficacy remains inconsistent and inconclusive. The variability in outcomes, including diminished effects over time despite repeated FMT, underscores the need for larger, well-controlled trials. Only one randomized controlled trial (RCT) has compared FMT with sham transplantation, but the sample size was very small. Other studies are limited by factors such as small sample sizes, lack of control groups, short follow-up periods, and inconsistent methodologies, making it challenging to draw definitive conclusions. While gut dysbiosis likely plays a role in CD pathogenesis, its causative role remains uncertain. Current evidence does not support FMT as a reliable treatment for inducing or maintaining remission in CD, though it appears generally safe. Larger, standardized, RCTs are necessary to clarify the therapeutic role of FMT in CD management.

摘要

克罗恩病(CD)是一种特发性、慢性且复发性的胃肠道炎症性疾病。最近的研究表明肠道微生物群在克罗恩病中可能发挥作用,尤其是菌群失调——肠道细菌失衡。虽然在克罗恩病中始终观察到菌群失调,但它是该疾病的原因还是结果仍不确定。鉴于其与克罗恩病的关联,人们已探索了粪便微生物群移植(FMT)的治疗潜力。本综述探讨了肠道微生物群在克罗恩病中的作用,评估了益生菌和粪便微生物群移植的治疗潜力,并强调了当前的研究结果和局限性。分析了关于克罗恩病中肠道菌群失调、益生菌和粪便微生物群移植之间关系的关键研究,重点关注随机试验、荟萃分析和临床观察。菌群失调是克罗恩病的一个持续特征,但其致病作用仍不清楚。益生菌、益生元及合生元在诱导或维持克罗恩病缓解方面未显示出疗效。粪便微生物群移植显示出作为克罗恩病治疗选择的潜力,但其疗效仍不一致且尚无定论。结果的变异性,包括尽管重复进行粪便微生物群移植但随着时间推移效果减弱,凸显了开展更大规模、严格对照试验的必要性。仅有一项随机对照试验(RCT)将粪便微生物群移植与假移植进行了比较,但样本量非常小。其他研究受到样本量小、缺乏对照组、随访期短和方法不一致等因素的限制,难以得出明确结论。虽然肠道菌群失调可能在克罗恩病发病机制中起作用,但其致病作用仍不确定。目前的证据不支持粪便微生物群移植作为诱导或维持克罗恩病缓解的可靠治疗方法,尽管它总体上似乎是安全的。需要开展更大规模、标准化的随机对照试验来阐明粪便微生物群移植在克罗恩病管理中的治疗作用。

相似文献

3
Stem cell transplantation for induction of remission in medically refractory Crohn's disease.
Cochrane Database Syst Rev. 2022 May 13;5(5):CD013070. doi: 10.1002/14651858.CD013070.pub2.
4
Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years.
Cochrane Database Syst Rev. 2025 Jul 10;7(7):CD015875. doi: 10.1002/14651858.CD015875.
5
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
7
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2.
9
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
10
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.

本文引用的文献

1
Role of gut microbiota in Crohn's disease pathogenesis: Insights from fecal microbiota transplantation in mouse model.
World J Gastroenterol. 2024 Aug 21;30(31):3689-3704. doi: 10.3748/wjg.v30.i31.3689.
3
Probiotics for inflammatory bowel disease: Is there sufficient evidence?
Open Life Sci. 2024 Apr 5;19(1):20220821. doi: 10.1515/biol-2022-0821. eCollection 2024.
4
AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.
Gastroenterology. 2024 Mar;166(3):409-434. doi: 10.1053/j.gastro.2024.01.008.
5
Probiotics, prebiotics, and postbiotics in health and disease.
MedComm (2020). 2023 Nov 4;4(6):e420. doi: 10.1002/mco2.420. eCollection 2023 Dec.
6
Fecal transplantation for treatment of inflammatory bowel disease.
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD012774. doi: 10.1002/14651858.CD012774.pub3.
7
Gut microbiota in the early stage of Crohn's disease has unique characteristics.
Gut Pathog. 2022 Dec 14;14(1):46. doi: 10.1186/s13099-022-00521-0.
9
Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.
Microorganisms. 2021 Apr 30;9(5):977. doi: 10.3390/microorganisms9050977.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验